Irish OTC firm Perrigo rejects Mylan’s raised bid
Earlier this month, Mylan offered to buy Perrigo in a deal valued at nearly $29bn, under which Perrigo shareholders would receive $205 per share. However, board of directors
The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) have granted paediatric clinical trial waivers to Shanton Pharma for its lead candidate SAP-001, easing the drug’s regulatory paths to approval.
IC, commonly referred to as painful bladder syndrome (PBS), is a chronic disease characterized by bladder pressure, bladder pain, urinary urgency and/or urinary frequency. It affects an estimated